TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8457038
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micrograms twice daily for 14 days)
Study: 11381581
Drug: All implants
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implants
Study: 29189275
Drug: US-assisted LSGB
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-assisted LSGB with 10 mL of 0.25% levobupivacaine
Study: 29189275
Drug: FL-guided LSGB
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL-guided LSGB with 10 mL of 0.25% levobupivacaine
Study: 24717789
Drug: GSK2190915 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 200 mg
Study: 18441680
Drug: Thiotorpium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotorpium bromide (TB) 18 mcg/day for one year, almitrine 10 mg/kg/day for 3 months, and an 8 week course of pulmonary rehabilitation (PR)
Study: 15029983
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral methadone tablet
Study: 15029983
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sublingual buprenorphine tablet
Study: 10966839
Drug: GP‐C (glycosaminoglycan
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP‐C (glycosaminoglycan polypeptide association complex) 2 ml intramuscularly, 10 courses over 5 years (15 injections per course, twice weekly)
Study: 22051419
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion at a dose of 0.1 μg/kg/min with an initial bolus (12 μg/kg for 10 minutes) after anesthesia induction (Group C)
Study: 22051419
Drug: Prophylactic IABP
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic IABP one day before surgery and levosimendan infusion (Group B)
Study: 21138627
Drug: Without anti-viral
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without anti-viral therapy (study group)
Study: 21138627
Drug: Lamivudine therapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine therapy (control group)
Study: 18207017
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient (MMN) supplementation in anaemic women (Hb <110 g/L)
Study: 15985134
Drug: L‐aspartate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐aspartate and L‐glutamate-enriched cardioplegia (13 mmol/L)
Study: 10391395
Drug: Metformin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (250 mg three times daily for 12 months)
Study: 8683251
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional chemotherapy)
Study: 8683251
Drug: Early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose therapy (HDT)
Study: 6144125
Drug: Haloperidol 1
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1 mg, 3 mg, and 6 mg
Study: 6144125
Drug: Propericiazine 10
Normalized name: propericiazine 10 MG per 5 ML Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propericiazine 10 mg and 30 mg
Study: 6144125
Drug: Propericiazine 60
Normalized name: Propericiazine
DrugBank: Periciazine (DB01608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propericiazine 60 mg
Study: 30681754
Drug: Opicapone 50
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 50 mg (open-label phase)
Study: 30383670
Drug: Microecological preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microecological preparation supplementation
Study: 25036712
Drug: Open-label levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label levodopa treatment
Study: 9199818
Drug: rt-PA, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA, 100 mg over 2 h (Group A)
Study: 9199818
Drug: rt-PA, 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA, 0.6 mg/kg, maximum dose 50 mg, over 15 min (Group B)
Study: 3900392
Drug: Amflutizole 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amflutizole 500 mg dosage
Study: 28842727
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (loading dose of 540,000 IU and five monthly maintenance doses of 90,000 IU)
Study: 25813216
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 15 mg
Study: 25813216
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 30 mg
Study: 25813216
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 45 mg
Study: 25813216
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 60 mg
Study: 25813216
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 90 mg
Study: 25813216
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER (all doses)
Study: 17279096
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin solution (5 mg/ml)
Study: 15476909
Drug: Subhypnotic-dose propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subhypnotic-dose propofol 1.0 mg/kg per hour combined with dexamethasone 8 mg
Study: 15476909
Drug: Subhypnotic-dose propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subhypnotic-dose propofol 1.0 mg/kg per hour alone
Study: 8605519
Drug: 6% glucose/sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% glucose/sucrose solution
Study: 8605519
Drug: Placebo (artificially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (artificially flavored and sweetened solution)
Study: 821050
Drug: Cooling treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling treatment with 'Cryogel'
Study: 28576892
Drug: Traditional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional and complementary medicine interventions (ear and body acupuncture, aromatherapy) in combination with nicotine replacement therapy (NRT) and counselling
Study: 28576892
Drug: Conventional cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional cessation methods (nicotine replacement therapy (NRT), counselling)
Study: 25420534
Drug: Armillarisin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armillarisin A 10 mg enema in 100 ml saline
Study: 25420534
Drug: Armillarisin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armillarisin A 10 mg and dexamethasone 5 mg enema in 100 ml saline
Study: 25420534
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg enema in 100 ml saline
Study: 17012628
Drug: Bosentan plus
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan plus inhaled iloprost (combination group)
Study: 11692092
Drug: Intranasal heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heparin
Study: 9113630
Drug: High-AA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-AA diet (1.5 g/d of AA in the form of a triglyceride containing 50% AA)
Study: 9113630
Drug: Low-AA diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-AA diet (210 mg/d of AA)
Study: 18982335
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol (Group T)
Study: 18982335
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol with 0.5 mg kg(‐1) ketamine (Group TK)
Study: 18982335
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ropivacaine (Group R)
Study: 18982335
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ropivacaine with 0.5 mg kg(‐1) ketamine (Group RK)
Study: 17907228
Drug: Ganoderma lucidum
Normalized name: GANODERMA LUCIDUM STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganoderma lucidum (4 gm) and San Miao San (2.4 gm) daily
Study: 11907486
Drug: Saquinavir 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 50 mg/kg tid alone
Study: 11907486
Drug: Saquinavir 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 50 mg/kg tid plus nelfinavir 30 mg/kg tid
Study: 11907486
Drug: Saquinavir (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir (any dosage)
Study: 10096977
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass equipment
Study: 2082316
Drug: Ketorolac active/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac active/heparin dummy
Study: 2082316
Drug: Ketorolac active/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac active/heparin active
Study: 2082316
Drug: Heparin active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin active
Study: 2082316
Drug: Ketorolac dummy/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac dummy/heparin active
Study: 29374963
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children (UP‐C)
Study: 25833066
Drug: Conventional inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inhaled corticosteroid (ICS)
Study: 26060627
Drug: Emotional intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Emotional intelligence training (12 sessions, 50 minutes each, twice a week)
Study: 21372765
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily 1 sachet of probiotic + high-fibre diet (Group B)
Study: 21372765
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily 2 sachets of probiotic + high-fibre diet (Group C)
Study: 17348994
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (TC) cream applied once daily for 8 weeks
Study: 17348994
Drug: Hydroquinone (HQ)
Normalized name: Hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone (HQ) cream applied twice daily for 8 weeks
Study: 17348994
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (TC) cream and Hydroquinone (HQ) cream
Study: 17190958
Drug: Oxcarbazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (600 mg BID)
Study: 17190958
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without oxcarbazepine
Study: 14567803
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine 30 ml instilled into the pelvic cavity and over the diaphragmatic vault (Group A)
Study: 14567803
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine 30 ml instilled (Group B)
Study: 14567803
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 30 ml instilled (Group C)
Study: 14567803
Drug: No intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intraperitoneal agent (Group D)
Study: 10469856
Drug: Routine hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine hemodialysis (135-140 mEq/L sodium bath)
Study: 10469856
Drug: Hypernatric hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypernatric hemodialysis (150-155 mEq/L sodium bath)
Study: 8740048
Drug: SDZ EAA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SDZ EAA 494 single dose (1-50 mg)
Study: 8740048
Drug: SDZ EAA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SDZ EAA 494 multiple doses (25 mg once or twice daily for 1 week)
Study: 1874211
Drug: Intrapleural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural bupivacaine (10 ml of 0.25% bupivacaine with 1:200,000 adrenaline every 8 h for 4 days)
Study: 1874211
Drug: Intrapleural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural saline (10 ml normal saline every 8 h for 4 days)
Study: 6577782
Drug: Gemfibrozil, 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil, 1,200 mg/day
Study: 21574800
Drug: Medpor® wedge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medpor® wedge implant
Study: 19687575
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy and exercise (MTEX)
Study: 19687575
Drug: Electrophysical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysical agents and exercise (EPAX)
Study: 8409070
Drug: Flosequinan 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 50, 100 or 150 mg daily (short-term administration)
Study: 8409070
Drug: Flosequinan 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 50, 100 or 150 mg daily (long-term administration after 8 weeks)
Study: 3898833
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g in the morning and 2 g at night)
Study: 29391385
Drug: Oral nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nitazoxanide
Study: 12711404
Drug: Interval medication
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval medication
Study: 12742493
Drug: Sirolimus (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (2 mg/d) in one-haplotype living-related kidney allografts
Study: 12742493
Drug: Sirolimus (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (2 mg/kg per day) in one-haplotype living-related kidney allografts
Study: 12742493
Drug: Sirolimus (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (2 mg/day) in fully mismatched living kidney allografts
Study: 12742493
Drug: Sirolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (target trough concentrations 8-12 ng/mL) in high-risk black ethnicity recipients
Study: 12742493
Drug: Sirolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (target trough concentrations 15-20 ng/mL) in high-risk black ethnicity recipients
Study: 10321420
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (100 mg)
Study: 10321420
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin (100 mg, 60-minute infusion)
Study: 10321420
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and IV formulations
Study: 1827086
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fosinopril
Study: 1827086
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fosinopril
Study: 1827086
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg fosinopril
Study: 1827086
Drug: Fosinopril (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10-80 mg) with or without chlorthalidone
Study: 6887757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cotrimoxazole, polymyxin B and nystatin (group A)
Study: 6887757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nalidixic acid, polymyxin B, neomycin and nystatin (group B)
Study: 31974022
Drug: Prompt describing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt describing adulterants as pharmacologically-active, potentially-harmful compounds
Study: 26600270
Drug: IL-2 infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-2 infusion
Study: 22136163
Drug: levodopa/carbidopa intestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/carbidopa intestinal gel
Study: 16301268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EST and EPWA
Study: 7852210
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) for treating maternal pregnancy anemia; specific dosage and duration not mentioned.
Study: 1006255
Drug: RU 43-715
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 43-715 (nonsteroid anti-inflammatory agent)
Study: 25762461
Drug: Standard cilengitide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cilengitide (2000 mg 2×/wk; n = 88)
Study: 25762461
Drug: Intensive cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cilengitide (2000 mg 5×/wk during wk 1‐6, thereafter 2×/wk; n = 88)
Study: 23650397
Drug: GSK650394 (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK650394 (small molecule inhibitor for SGK1)
Study: 23650397
Drug: GSK650394 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK650394 combined with RU486 (GR antagonist)
Study: 21135196
Drug: MBSR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBSR therapy plus traditional therapy
Study: 17011443
Drug: Whole-pelvis radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-pelvis radiotherapy (WP RT) + neoadjuvant and concurrent hormonal therapy (N&CHT)
Study: 17011443
Drug: Mini-pelvis radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-pelvis radiotherapy (MP RT) + neoadjuvant and concurrent hormonal therapy (N&CHT)
Study: 17011443
Drug: Prostate-only radiotherapy
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-only radiotherapy (PO RT) + neoadjuvant and concurrent hormonal therapy (N&CHT)
Study: 11766085
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel cleansing plus oral antimicrobial prophylaxis with kanamycin and erythromycin for 2 days prior to surgery (group 2)
Study: 9806257
Drug: Tibolone treatment
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone treatment
Study: 8273859
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g intravenously every 8 hours for 48 hours (8 doses, n = 425)
Study: 8273859
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g 1 hour prior to surgery plus 1.5 g every 12 hours for 3 additional doses (4 doses, n = 277)
Study: 3446308
Drug: Phenelzine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (high dose)
Study: 2706320
Drug: BY912 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BY912 400 mg theophylline capsules
Study: 2706320
Drug: Theo-24 capsules
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theo-24 capsules
Study: 23228670
Drug: Morphine 0.1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1mg (Group A)
Study: 23228670
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 μg (Group B)
Study: 23228670
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 μg + bilateral TAP block (Group C)
Study: 21310284
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA, 10 mg/day)
Study: 21310284
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA, 50 mg/day)
Study: 12869082
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg twice daily plus 20 mg of omeprazole daily
Study: 10597744
Drug: Sequential intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intensification program (SEQ‐INT)
Study: 10597744
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen (CMF)
Study: 8983396
Drug: Clinoril tablets
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinoril tablets
Study: 30863028
Drug: CAU (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAU (no active treatment)
Study: 23593932
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg per day maximum)
Study: 14987306
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily plus cetirizine (CTZ) 10 mg
Study: 14987306
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily plus montelukast (MSK) 10 mg